Lumida
/ALMS
⌘K
Alumis Inc

Alumis Inc

ALMS
$9.18USD-7.27%-0.72 today

MARKET CAP

1.2B

P/E (TTM)

FWD P/E

DAY RANGE

$9 – $10

52W RANGE

$4
$31

AI Summary

Stalk
Sell NowMedium

In Stage 4 decline, the active Support Failure pattern confirms sellers’ control and medium-term bearish bias. Price is trading well below declining 9/20 EMAs with accelerated downside momentum and no stabilization in sight. Selling into any relief rallies toward resistance is advised immediately.

  • Envudeucitinib ONWARD3 trial: 75% PASI 90 & 54% PASI 100 at 48 weeks
  • $502.3M cash & equivalents support operations into Q4 2027
  • Q2 2026 revenue $1.7M down 37% YoY vs. $3.47M consensus
Full analysis →
Insider Trades9 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Aug 3, 2026SellALMSSanam PangaliChief Legal Officer1,364$26.37$1.2B-70.72%+144.15%$36.0K-12.28%Buy Now
Aug 3, 2026SellALMSJorn DrappaChief Medical Officer2,447$26.37$1.2B-70.72%+144.15%$64.5K-4.12%Buy Now
Aug 3, 2026SellALMSMark Christopher BradleyChief Development Officer2,572$26.37$1.2B-70.72%+144.15%$67.8K-5.03%Buy Now
Aug 3, 2026SellALMSDavid M GoldsteinChief Scientific Officer2,596$26.37$1.2B-70.72%+144.15%$68.5K-7.73%Buy Now
Aug 3, 2026SellALMSRoy C. HardimanChief Business & Strategy Ofcr2,692$26.37$1.2B-70.72%+144.15%$71.0K-1.28%Buy Now
Aug 3, 2026SellALMSJohn R. SchroerChief Financial Officer3,282$26.37$1.2B-70.72%+144.15%$86.5K-11.72%Buy Now
Jul 6, 2026SellALMSSanam PangaliChief Legal Officer10,000$16.53$1.2B-70.72%+144.15%$165.3K+0.00%Buy Now
May 22, 2026BuyALMSJorn DrappaChief Medical Officer26,852$6.65$1.2B-70.72%+144.15%$178.6K+6.70%Buy Now
Apr 1, 2025BuyALMSMartin BablerPresident, CEO and Chairman15,650$6.44$1.2B-70.72%+144.15%$100.7K+17.23%Buy Now